Patents by Inventor Urmas Arumäe

Urmas Arumäe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7642047
    Abstract: The invention provides methods and compositions for identifying agents which modulate cell death, indicated e.g. by the expression of caspase-2 and/or caspase-7, in GDNF family growth factor deprived neuronal or nonneuronal cells. The methods for identifying such agents find particular application in drug development.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: January 5, 2010
    Inventors: Urmas Arumäe, Li-Ying Yu, Mart Saarma
  • Patent number: 6905817
    Abstract: Methods for screening for agonists and antagonists of GPI-anchored independent intracellular signaling resulting in [Ca2+]i elevation, ERK1, ERK2 and CREB phosphorylation, and Src family kinase activation are described, as well as methods for treatment involving administration of agonists/antagonists of such signaling.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: June 14, 2005
    Assignee: Licestia Ltd.
    Inventors: Alexey Vladimirovich Titievsky, Dmitri Poteriaev, Urmas Arumäe, Mart Saarma
  • Patent number: 6696259
    Abstract: Receptors for Glial Cell Line-Derived Neurotrophic Factor (GDNF), their cellular expression, isolation, biochemical characterization, and sequences are disclosed. c-RET is disclosed as one receptor for GDNF; additional novel receptors are also disclosed. The preparation of monoclonal antibodies directed against GDNF is also disclosed.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: February 24, 2004
    Assignee: Licentia Ltd.
    Inventors: Carlos F. Ibanez, Miles Trupp, Mart Saarma, Hannu Sariola, Urmas Arumäe, Petro Suvanto